Logo

TGen's Drug Development Group to Use Mission3 Product-Lifecycle Software

Aug 15, 2007
NEW YORK (GenomeWeb News) - The Translational Genomics Research Institute’s TD2 drug-development arm has agreed to use product-lifecycle software from Mission3, the organizations said recently.
 
TD2 will use the company’s MissionFire and FastCrossing software to help manage its drug development process.
 
FastCrossing is a graphical, web-based tool used in application submissions, while MissionFire is used in document and project management.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.